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Fixed drug eruptions (FDE) represent a skin syndrome
expressed clinically as a round, erythematous and edematous pla-
que, involving occasionally mucous membranes, that often recur
in the same location, developing hyperpygmentation.1 This type
of cutaneous hypersensitivity reaction is mediated by cytotoxic
CD4þ, CD8þ, and CD56þ Tcells (type IVc reaction), and its progres-
sion is believed to be limited by regulatory T cells.1e3 Nevertheless,
other clinical variants have been described, including dermato-
graphic4 or papular eruptions.5 Either local anesthetics (LA)6 or
non-steroidal anti-inﬂammatory drugs (NSAIDS)7 represent two
major families of drugs causing FDE.
We present two patients who suffered from atypical FDE types.
Patient 1: A 30-year-old woman with a personal history of rhino-
conjunctivitis due to pollen sensitivity, and diagnosed with
congenital multiple nevus syndrome. She denied having any
allergic symptoms to latex exposure. This patient developed, in
two different occasions after nevus exeresis (on the back and
the neck, respectively), one itching and erythematous urticarial
wheal on the outer face of her right arm. In both cases, the lesion
appeared 20 min after the administration of Scandinibsa™
(mepivacaine 2% [20 mg/ml], Inibsa, Barcelona, Spain) and spon-
taneously disappeared 15 min later without leaving neither
desquamation nor hyperpigmentation. One month later, an aller-
gological workup was undergone after granting her informed
consent. Patient 2: A 50-year-old womanwithout a personal or fa-
milial history of atopy. Eight years ago, she had sufferedmore than
10 episodes of an itching and erythematous isolated urticarial
wheal always located over the upper abdomen (epigastrium). It
appeared after taking metamizole or acetaminophen for different
pains or upper respiratory infections. All the episodes started
15e20 min after the drug intake and disappeared within 30 min
spontaneously with no residual skin lesions. After the last
episode, she has tolerated ibuprofen, dexketoprofen, and other
NSAIDS. Two months later, an allergy study was undergone after
receiving her informed consent.
We performed an allergological study for both cases. Patient 1:
Skin prick testing (SPT) and intradermal tests (with inmediate and
late readings at 48 and 72 h) with commercial Mepivacaina™ 1%
(Braun, Barcelona, Spain) (10 ml of aqueous solution of mepiva-
caine 1% [10 mg/ml], sulphites-, and parabens-free) were carried
out. The SPT was made with an undiluted solution of the commer-
cial drug. For intradermal tests, 0.02 ml from two different concen-
trations were injected sequentially: 0.02 mg (1:10 dilution inPeer review under responsibility of Japanese Society of Allergology.
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epinephrine were also performed.
All cutaneous tests were negative. Subsequently, a graded-dose
subcutaneous challenge test (0.1e0.5e1 ml out of a 10 mg/ml con-
centration) was carried out. Twenty minutes after accumulating
0.6 ml of Mepivacaina™ 1% (Braun, Barcelona, Spain) on the left
shoulder, itching, erythema and one hive appeared on the outer
face of her right arm, in the same place and with the same charac-
teristics as the patient had experienced on the previous two occa-
sions. This lesion spontaneously disappeared in 30 min. Two
months after ﬁnishing this study, the patient needed a new exeresis
of four nevus located on her face and neck using Lidocaina™ 1%
(Braun, Barcelona, Spain) (10 ml of an aqueous solution of lidocaine
1% [10 mg/ml], sulphites-, and parabens-free). Twenty minutes af-
ter the intervention, the same cutaneous lesion appeared again on
the outer face of her right arm (Fig. 1A).
The biopsy conﬁrmed an urticarial lesion (Fig. 1B, C). An increase
in the lymphocyte number was discarded. Stains for mast cells with
Giemsa and immunohistochemistry for CD117 did not show any in-
crease in the number of mast cells, hence discarding a mast cell
accumulate, namely mastocytoma, or a ﬂare-up phenomenon. In
fact, no injection of LA was administered previously on the site
where the urticaria took place, discarding a hypothetical ﬂare-up
reaction.
In order to evaluate a possible cross-reactivity among different
LA, and to offer a safe alternative to the patient, one week later,
we carried out a SPT and intradermal tests with commercial Bupi-
vacaina™ 0.25% (Braun, Barcelona, Spain) (10 ml of an aqueous
solution of bupivacaine 0.25% [2.5 mg/ml], sulphites-, and
parabens-free). The SPT performed with an undiluted solution of
the commercial drug was negative. For intradermal tests we used
1:10 and 1:1 dilutions in saline solution, with negative results.
We carried out a double-blind, placebo-controlled challenge test
with bupivacaine at therapeutic doses subcutaneously, reaching
1.6 ml accumulated, and the patient experienced no reaction. Of
note, all the SPT and intradermal tests were performed on the volar
face of her left forearm, and all the challenge tests, on the outer face
of her left shoulder.
Patient 2: Due to the fact that the patient reactions did not have
clinical signiﬁcance, we performed an open challenge test with
acetaminophen and metamizole in different days. In both cases, a
unique urticarial wheal located on epigastrium appeared in
15 min (Fig. 2A), being spontaneously resolved in 30 min in the
acetaminophen case, and taking a biopsy in the metamizole case.
The biopsy conﬁrmed a neutrophilic-type urticarial pattern
(Fig. 2B, C). Staining for mast cells did not show any increase in
the number of these cells. An increase in the lymphocyte number
was also discarded. Due to the evanescent nature of the lesions,evier B.V. All rights reserved.
Fig. 1. (A) Hive located on the outer face of the right arm after challenging with lidocaine. (B) Mild dermal edema, lymphatic and small blood vessel dilation, and perivascular
lymphocyte inﬁltrate (hematoxylin and eosin stain, original magniﬁcation 10). (C) Large numbers of perivascular and small vessel wall eosinophils (hematoxylin and eosin stain,
original magniﬁcation 40).
Fig. 2. (A) Hive located on epigastrium after an oral challenge test with metamizole. (B) Mild perivascular inﬂammatory inﬁltrate in the deeper and upper dermis, with neutrophils
and occasional eosinophils (hematoxylin and eosin stain, original magniﬁcation 20). (C) Discreet dilation of small blood vessels with intravascular neutrophils and a mild dermal
edema (hematoxylin and eosin stain, original magniﬁcation 40).
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which was conﬁrmed by skin biopsies. In spite of this, we per-
formed patching test with the implicated drugs in petrolatum
20% (mepivacaine, lidocaine, metamizole and acetaminophen) at
the site of a previous lesion spontaneously resolved and on skin
never injured, in order to discard a T-cell-mediated mechanism.
The results were negative in both patients, supporting a type I hy-
persensitivity reaction and discarding a type IV mechanism.
To the best of our knowledge, these two cases represent the ﬁrst
reported patients diagnosed with ﬁxed drug urticaria. Morais-
Almeida et al.8 reported a patient that exhibited an extensive local
urticaria after local lidocaine, where skin tests with lidocaine,
bupivacaine, mepivacaine, and ropivacaine, were positive. Never-
theless, Prieto et al.9 reported a patient that reacted to mepiva-
caine, with a cross-reactivity with ropivacaine, but tolerating
lidocaine and bupivacaine. The patient s1 presented an unusual
immediate hypersensitivity reaction to mepivacaine and lidocaine,
and a good tolerance to bupivacaine was demonstrated. And
regarding to NSAIDS, the site of involvement of the FDE for either
acetaminophen or metamizole was on the trunk in a series of 105
patients,10 as in the patient s2. This patient tolerates the rest of
NSAIDS.
In conclusion, herein, we present two exclusive cases of a ﬁxed
drug reactionmanifested as an urticaria, always located in the same
area in both patients, after the injection of mepivacaine and lido-
caine in different places, or after taking acetaminophen and meta-
mizole. Further investigation must be carried out in order to
enlighten the real immunologic mechanism involved in this kind
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